Allogene

AACR 2023 – Moderna's immunotherapeutic splash
AACR 2023 – Moderna's immunotherapeutic splash
EP Vantage
AACR
Moderna Therapeutics
Allogene
AstraZeneca
Merck
Roche
Novartis
Eli Lilly
Innovent
Springworks
Biogene
Relay Therapeutics
Vivace Therapeutics
Flag link:
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
Global Newswire
Allogene
large B cell lymphoma
clinical trials
ALLO-501a
CAR-T
Flag link:
As biotech retreats, gene therapy companies retrench and redraw plans
As biotech retreats, gene therapy companies retrench and redraw plans
BioPharma Dive
biotech
gene therapy
layoffs
R&D
Bluebird Bio
Allogene
uniQure
Flag link:
A late Christmas present for Allogene
A late Christmas present for Allogene
EP Vantage
Allogene
JPMHC 2022
FDA
CAR-T
Flag link:
10 clinical trials to watch in the first half of 2022
10 clinical trials to watch in the first half of 2022
BioPharma Dive
clinical trials
Pfizer
Arena Pharmaceuticals
etrasimod
Sanofi
GSK
vaccines
COVID-19
Roche
gantenerumab
AbbVie
Gilead Sciences
Trodelvy
Karuna Therapeutics
KarXT
Intercept Pharma
obeticholic acid
Allogene
ALLO-501a
Flag link:
Off-the-shelf CAR-T, a Tagrisso rival and the next breast cancer drugs: a look ahead at ASCO
Off-the-shelf CAR-T, a Tagrisso rival and the next breast cancer drugs: a look ahead at ASCO
BioPharma Dive
ASCO 2021
Allogene
CAR-T
Bristol Myers Squibb
EQRx
Flag link:
Allogene, broadening its reach, helps start a new biotech in China
Allogene, broadening its reach, helps start a new biotech in China
BioPharma Dive
Allogene
Overland Pharmaceuticals
China
cell therapies
Allogene Overland Pharma
Flag link:
ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field
ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field
Fierce Biotech
ASH2020
Allogene
CAR-T
Flag link:
Asco 2020 movers – cell therapy companies dominate the risers
Asco 2020 movers – cell therapy companies dominate the risers
EP Vantage
ASCO 2020
cell therapy
Adaptimmune
Allogene
Iovance
Flag link:
Allogene’s ALLO-501 Shows Positive Results in Its Phase I ALPHA Trial
Allogene’s ALLO-501 Shows Positive Results in Its Phase I ALPHA Trial
BioSpace
Allogene
ASCO 2020
ALLO-501
clinical trials
refractory indolent non-Hodgkins lymphoma
Flag link:
ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma
ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma
Fierce Biotech
Allogene
ASCO 2020
CAR-T
ALLO-501
ALLO-647
lymphoma
Flag link:
Allogene gives first look at an 'off the shelf' cell therapy for lymphoma
Allogene gives first look at an 'off the shelf' cell therapy for lymphoma
BioPharma Dive
Allogene
ASCO 2020
cell therapy
non-Hodgkin lymphoma
ALLO-501
ALLO-647
Flag link:
Two biotech CEOs test positive for Covid-19 after attending investor conference
Two biotech CEOs test positive for Covid-19 after attending investor conference
MedCity News
Pharma CEOs
Allogene
Apellis Pharmaceuticals
Arie Belldegrun
Cedric Francois
COVID-19
Biogen
Flag link:
Allogene, SpringWorks to Test Drug Combo in Multiple Myeloma Trial
Allogene, SpringWorks to Test Drug Combo in Multiple Myeloma Trial
Xconomy
SpringWorks Therapeutics
Allogene
Multiple Myeloma
clinical trials
ALLO-715
nirogacestat
Flag link:
A Record Year: A Look at the Biotech IPOs for Q4 2018
A Record Year: A Look at the Biotech IPOs for Q4 2018
BioSpace
IPOs
biotech
Moderna Therapeutics
Allogene
Rubius Therapeutics
Kodiak Sciences
Guardant Health
SI Bone
Flag link:
#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of immunosuppression is crucial
#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of immunosuppression is crucial
Endpoints
ASH 2018
Allogene
CAR-T
ALL
Flag link:
Allogene raises $324M in year's largest biotech IPO on NASDAQ
Allogene raises $324M in year's largest biotech IPO on NASDAQ
BioCentury
Allogene
IPOs
cell therapy
NASDAQ
Flag link:
Allogene IPO could be year's largest biotech listing on NASDAQ
Allogene IPO could be year's largest biotech listing on NASDAQ
BioCentury
IPOs
NASDAQ
Allogene
CAR-T
Flag link:
Allogene Therapeutics Announces Filing For IPO
Allogene Therapeutics Announces Filing For IPO
CP Wire
Allogene
IPOs
CAR-T
Flag link:
Allogene Therapeutics Banks $120 Million in Private Financing
Allogene Therapeutics Banks $120 Million in Private Financing
CP Wire
Allogene
Gilead Sciences
Pfizer
Flag link:

Pages